NR1H4 and metabolic dysfunction-associated steatohepatitis: In the effort to develop nonsteroidal FXR agonists for the treatment of NASH and other bile acid‐related diseases, a 2021 study[112] reported the synthesis of a series of novel compounds based on modifications of GW4064 (1), specifically replacing its stilbene group with a ketoxime ether moiety.